Drug Profile
Velaglucerase alfa - Takeda
Alternative Names: GA-GCB; GCB; Gene-activated glucocerebrosidase; Glucocerebrosidase - Takeda; Glucosylceramidase - Takeda; VprivLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Shire Pharmaceuticals Group
- Developer Shire; Takeda
- Class Glucosidases; Recombinant proteins
- Mechanism of Action Glucosylceramidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gaucher's disease type I
- No development reported Gaucher's disease type III
Most Recent Events
- 03 Jan 2023 Phase-III clinical trials in Gaucher's disease type I (In children, In adults, In adolescents, In the elderly) in China (IV) (NCT05529992; EudraCT2022-002323-35)
- 07 Sep 2022 Takeda plans a phase III trial for Gaucher's disease type I (In children, In adolescents, In adults) in China (IV, Infusion) (NCT05529992)
- 19 Sep 2019 Shire plans a clinical trial for Gaucher's Disease in Canada (NCT04094181)